Genes in panel

Hereditary Neuropathy

Gene: ATAD3A

Green List (high evidence)

ATAD3A (ATPase family AAA domain containing 3A, Ensemblv115)
EnsemblGeneIds (GRCh38): ENSG00000197785
EnsemblGeneIds (GRCh37): ENSG00000197785
OMIM: 612316, ClinGen, DECIPHER
ATAD3A is in 11 panels

1 review

Sangavi Sivagnanasundram (Melbourne Health)

Green List (high evidence)

Is a syndromic neurodevelopmental disorder characterized by delayed psychomotor development, intellectual disability, truncal hypotonia, spasticity, and peripheral neuropathy.

Neuropathy like phenotypes are only present in individuals with monoallelic variants in ATAD3A

PMID: 27640307
5 affected individuals from 5 unrelated families with the recurrent heterozygous de novo mutation (p.Arg528Trp) with all individuals presenting with symptoms of peripheral neuropathy.

Fly functional study conducted that showed a dramatic reduction in survival in the presence of the mutant protein suggesting it is highly toxic. The loss of function phenotype assiociated with bor was assessed by performing transmission electron microscopy (TEM) on the first larvae prior to their death and identified a dramatic decrease in mitochondrial content indicating a similarity in phenotype for both LoF and GoF.Therefore the mode of pathogenicity is suggestive of dominant negative.

AR inheritance is due to loss of function mutations in ATAD3A and is typically infantile onset.
Created: 2 Jun 2023, 9:42 a.m.

Mode of inheritance
BOTH monoallelic and biallelic, autosomal or pseudoautosomal

Phenotypes
Harel-Yoon Syndrome (MIM#6173183)

Publications

Mode of pathogenicity
Other

Details

Mode of Inheritance
MONOALLELIC, autosomal or pseudoautosomal, imprinted status unknown
Sources
  • Expert Review Green
  • Royal Melbourne Hospital
Phenotypes
  • Harel-Yoon Syndrome (MIM#6173183)
OMIM
612316
ClinGen
ATAD3A
DECIPHER
ATAD3A
Clinvar variants
Variants in ATAD3A
Penetrance
None
Publications
Mode of Pathogenicity
Other
Panels with this gene

History Filter Activity

Note: This information shows the history of the gene symbol, not the gene entity. Where the gene symbol for a gene has changed, this history may reference a different gene to the entry you are currently viewing.
8 Sep 2026, Gel status: 3

Entity classified by Genomics England curator

Zornitza Stark (Victorian Clinical Genetics Services)

Gene: atad3a has been classified as Green List (High Evidence).

8 Sep 2026, Gel status: 3

Set Phenotypes

Zornitza Stark (Victorian Clinical Genetics Services)

Phenotypes for gene: ATAD3A were changed from Global developmental delay, optic atrophy, axonal neuropathy, hypertrophic cardiomyopathy to Harel-Yoon Syndrome (MIM#6173183)

8 Sep 2026, Gel status: 3

Set publications

Zornitza Stark (Victorian Clinical Genetics Services)

Publications for gene: ATAD3A were set to

8 Sep 2026, Gel status: 3

Set mode of pathogenicity

Zornitza Stark (Victorian Clinical Genetics Services)

Mode of pathogenicity for gene: ATAD3A was changed from to Other

13 Jan 2020, Gel status: 3

Created, Added New Source, Set mode of inheritance, Set Phenotypes

Bryony Thompson (Royal Melbourne Hospital)

gene: ATAD3A was added gene: ATAD3A was added to Hereditary Neuropathy - complex_RMH. Sources: Royal Melbourne Hospital,Expert Review Green Mode of inheritance for gene: ATAD3A was set to MONOALLELIC, autosomal or pseudoautosomal, imprinted status unknown Phenotypes for gene: ATAD3A were set to Global developmental delay, optic atrophy, axonal neuropathy, hypertrophic cardiomyopathy